Vanguard Global Advisers
ARCT icon

Vanguard Global Advisers’s Arcturus Therapeutics ARCT Stock Holding History

Vanguard Global Advisers’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.2K Hold
8,507
– – ﹤0.01% 3019
2026
Q1 		$65.7K Buy
+8,507
New +$62.1K ﹤0.01% 2900

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Global Advisers's ARCT Position: Q2 2026 in Review

Vanguard Global Advisers held its Arcturus Therapeutics (ARCT) position steady in Q2 2026 at 8,507 shares worth $57.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3019.

Vanguard Global Advisers first reported a position in ARCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $65.7K in Q1 2026. 132 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Vanguard Global Advisers held 8,507 shares of Arcturus Therapeutics worth $57.2K as of Q2 2026.
  • Vanguard Global Advisers left its Arcturus Therapeutics share count unchanged in Q2 2026.
  • Arcturus Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3019 holding.
  • Vanguard Global Advisers first reported a position in Arcturus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Arcturus Therapeutics position peaked at $65.7K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.